Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

MaxCyte (MXCT)

Price 364.00p on 19-07-2024 at 16:30:02
Change -16.00p -4.21%
Buy 368.00p
Sell 360.00p
Buy / Sell MXCT Shares
Last Trade: Unknown 180.00 at 352.74805p
Day's Volume: 15,530
Last Close: 364.00p
Open: 370.00p
ISIN: US57777K1060
Day's Range 364.00p - 373.00p
52wk Range: 172.50p - 420.00p
Market Capitalisation: £381m
VWAP: 364.33587p
Shares in Issue: 105m

Recent Trades History MaxCyte (MXCT)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 180 352.74805p Currency Conversion
OTC Trade
15:09:02 - 19-Jul-24
Sell* 484 360.11p Ordinary
14:15:12 - 19-Jul-24
Sell* 484 360.11p Ordinary
14:07:09 - 19-Jul-24
Sell* 695 360.11p Ordinary
13:53:44 - 19-Jul-24
Sell* 3,336 360.10p Ordinary
13:43:45 - 19-Jul-24
Buy* 750 370.00p Ordinary
13:38:07 - 19-Jul-24
Unknown* 800 361.47982p Currency Conversion
OTC Trade
13:37:08 - 19-Jul-24
Unknown* 300 361.32527p Currency Conversion
OTC Trade
13:37:08 - 19-Jul-24
Sell* 2,484 370.00p Ordinary
13:36:57 - 19-Jul-24
Buy* 2,133 371.98p Ordinary
13:35:55 - 19-Jul-24

Share Price History for MaxCyte

Time period:
to
Date Open High Low Close Volume

Share News for MaxCyte

IN BRIEF: MaxCyte CEO Maher Masoud buys 100,000 shares

11th Jun 2024 11:10

MaxCyte Inc - Rockville, Maryland-based provider of cell engineering platform technologies - Says Chief Executive Officer Maher Masoud acquired 100,000 shares in the company between Friday and Monday. Masoud purchased the shares at an average of 489.07 US cents each in New York on the open market. These comprise his entire shareholding so far in MaxCyte, giving him an approximate 0.1% stake. Masoud, who became CEO in January, also holds a further 1.1 million options over MaxCyte's common stock and 400,000 performance stock units. Read More

UK shareholder meetings calendar - next 7 days

4th Jun 2024 14:27

Read More

IN BRIEF: MaxCyte inks deal with Legend Biotech for tech supply

22nd May 2024 21:51

MaxCyte Inc - Rockville, Maryland-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Inks strategic platform license agreement with Legend Biotech Corp, a firm focused in cell therapy. Under the terms of the agreement, Legend Biotech will get a non-exclusive worldwide license to use MaxCyte's Flow Electroporation technology and ExPERT platform in connection with the research, clinical development and commercialisation of cell-based therapeutical products. Accordingly, MaxCyte will be allowed to receive annual licensing fees and milestones from Legend during clinical development. Read More

MaxCyte shares rise amid double-digit revenue increase

8th May 2024 09:46

(Alliance News) - MaxCyte Inc on Wednesday reported a jump in its first quarter revenue, which it said was driven by its core business sales. Read More

LONDON BROKER RATINGS: Jefferies cuts AJ Bell; Deutsche likes ConvaTec

3rd May 2024 09:14

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday: Read More

FTSE 100 Latest
Value8,155.72
Change-49.17

Login to your account

Forgot Password?

Not Registered